Apparent clearance of sirolimus in heart transplant recipients: Impact of primary diagnosis and serum lipids

Therapeutic Drug Monitoring

Volumn 28, Issue 5, 2006, Pages 614-622

  Zahir, Hamim ^a   Keogh, Anne M ^b   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Apparent clearance; Heart transplant; Ischemic heart disease; NONMEM; Sirolimus; Triglyceride

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; NIFEDIPINE; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RIFAMPICIN; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL; AZATHIOPRINE; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ROXITHROMYCIN;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; EVALUATION; FEMALE; GENDER; HEART TRANSPLANTATION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MODEL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; TANDEM MASS SPECTROMETRY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; GRAFT RECIPIENT; HEART GRAFT; LOADING DRUG DOSE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOM ERROR;

ADOLESCENT; ADULT; AGED; CONFIDENCE INTERVALS; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; LIPIDS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; SIROLIMUS; CHOLESTEROL, HDL; HALF-LIFE; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; TRIGLYCERIDES;

EID: 33845687152     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000246765.05248.fa     Document Type: Article

References (26)

1. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573-585.
2. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22:101B-121B.
3. Kahan BD, Napoli KL, Sirolimus. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics. Baltimore: Lippincott Williams & Wilkins; 2006:595-616.
4. Brattstrom C, Sawe J, Jansson B, et al. Pharmacokinetics and safety of single oral doses of sirolimus rapamycin in healthy male volunteers. Ther Drug Monit. 2000;22:537-544.
5. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc. 1996;28:970-973.
6. Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997;61:416-428.
7. Streit F, Christians U, Schiebel HM, et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus rapamycin. by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos. 1996;24:1272-1278.
8. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
9. Brattstrom C, Sawe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit. 1997;19:397-406.
10. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37:405-415.
11. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694-2700.
12. Taylor PJ, Johnson AG. Quantitative analysis of sirolimus Rapamycin in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 1998;718:251-257.
13. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant. 2000;14:97-109.
14. Zimmerman JJ, Harper D, Getsy J, et al. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003;43:1168-1176.
15. Wu FL, Tsai MK, Chen RR, et al. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy. 2005;25:646-653.
16. Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol. 1999;39:1155-1161.
17. Akhlaghi F, Jackson CH, Parameshwar J, et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation. 2002;73:1258-1264.
18. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet. 2002;41:615-637.
19. Paine MF, Leung LY, Watkins PB. New insights into drug absorption: studies with sirolimus. Ther Drug Monit. 2004;26:463-467.
20. Yatscoff R, LeGatt D, Keenan R, et al. Blood distribution of rapamycin. Transplantation. 1993;56:1202-1206.
21. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther. 2001;69:32-40.
22. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J. 2004;6:28E.
23. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: Illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
24. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
25. Zahir H, McLachlan AJ, Nelson A, et al. Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients. Ther Drug Monit. 2005;27:422-430.
26. Booth BP, Gobburu JV. Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol. 2003;43:1307-1315.